4.7 Review

Inferior Vena Cava Filters to Prevent Pulmonary Embolism Systematic Review and Meta-Analysis

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 70, 期 13, 页码 1587-1597

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2017.07.775

关键词

bleed; mortality; prevention; risk; venous thromboembolism

资金

  1. Boston Scientific
  2. Abbott Vascular
  3. Medtronic
  4. Abiomed
  5. CathWorks
  6. Siemens
  7. BiO2 Medical
  8. Boehringer Ingelheim
  9. Bristol-Myers Squibb
  10. BTG EKOS
  11. Daiichi-Sankyo
  12. Janssen

向作者/读者索取更多资源

BACKGROUND Inferior vena cava (IVC) filters are widely used for prevention of pulmonary embolism (PE). However, uncertainty persists about their efficacy and safety. OBJECTIVES The authors conducted a systematic review and meta-analysis of the published reports on the efficacy and safety of IVC filters. METHODS The authors searched PubMed, the Cochrane Central Register of Controlled Trials, and ClinicalTrials. gov through October 3, 2016, for randomized controlled trials (RCTs) or prospective controlled observational studies of IVC filters versus none in patients at risk of PE. Inverse variance fixed-effects models with odds ratio (OR) as the effect measure were used for primary analyses. Main outcomes included subsequent PE, PE-related mortality, all-cause mortality, and subsequent deep vein thrombosis (DVT). RESULTS The authors' search retrieved 1,986 studies, of which 11 met criteria for inclusion (6 RCTs and 5 prospective observational studies). Quality of evidence for RCTs was low to moderate. Overall, patients receiving IVC filters had lower risk for subsequent PE (OR: 0.50; 95% confidence interval [CI]: 0.33 to 0.75); increased risk for DVT (OR: 1.70; 95% CI: 1.17 to 2.48); nonsignificantly lower PE-related mortality (OR: 0.51; 95% CI: 0.25 to 1.05); and no change in all-cause mortality (OR: 0.91; 95% CI: 0.70 to 1.19). Limiting the results to RCTs showed similar results. Findings were substantively similar across a wide range of sensitivity analyses. CONCLUSIONS Very few prospective controlled studies, with limited quality of evidence, exist regarding the efficacy and safety of IVC filters. Overall, filters appear to reduce the risk of subsequent PE, increase the risk for DVT, and have no significant effect on overall mortality. (C) 2017 by the American College of Cardiology Foundation.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据